Trieu Vuong purchased $11K of OTLC
Trieu Vuong (CHAIRMAN AND CEO) purchased 255,000 shares of Oncotelic Therapeutics, Inc. (OTLC) at $0.04 across 3 trades over 2026-06-22 to 2026-06-24.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO/Chairman’s open-market purchase details (dates, shares, price, and post-transaction holdings). This can slightly improve sentiment but does not provide new clinical, regulatory, or financial information.
Market read
Useful for tracking insider behavior in OTLC, but unlikely to drive a major repricing without accompanying company catalysts.
What to watch
The filing notes no pre-arranged 10b5-1 plan; traders may still want to check for other recent insider transactions and any concurrent financing/dilution risk typical for microcaps.
Background
The article is an SEC Form 4 insider transaction disclosure for Oncotelic Therapeutics, Inc. (OTLC).
Ticker impact
SEC Form 4 shows OTLC CEO/Chairman Trieu Vuong bought 255,000 shares at $0.0450/share across three trades (6/22-6/24).
Likely limited near-term impact; any effect would be sentiment-driven and short-lived unless followed by additional company-specific news.
The filing is primary-source and directly tied to OTLC, but the disclosed transaction size/value ($11.5k) is small relative to typical microcap price discovery and does not include new operational/financial guidance.
Market effects
No sector read-across; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine liquidity/portfolio actions and may not signal improved fundamentals, especially when the dollar value is small.
Key entities
- issuerOncotelic Therapeutics, Inc.
OTLC, the company whose insider transaction is disclosed on Form 4.
- insiderTrieu Vuong
Chairman and CEO; reported open-market purchase of OTLC shares.